Healthcare Industry News: LipiScan
News Release - May 5, 2016
TearScience(R) Introduces LipiScan(TM) for Rapid High Definition (HD) Meibomian ImagingLipiScan™ ushers in a new era of routine assessment of meibomian gland health. Swift image capture empowers Eye Care Professionals (ECPs) to regularly view structure of meibomian glands
MORRISVILLE, N.C., May 5, 2016 -- (Healthcare Sales & Marketing Network) -- TearScience, a privately held medical device company and manufacturer of LipiView® II and LipiFlow®, for the treatment of meibomian gland dysfunction (MGD), today announced the release of LipiScan, the first and only dedicated high definition (HD) gland imager that allows eye care professionals (ECPs) to efficiently evaluate meibomian glands in busy practices.
The new rapid imager was created with end users in mind. Fast and intuitive, LipiScan harnesses patented dynamic meibomian imaging (DMI) technology to produce high definition images of meibomian glands. LipiScan allows ECPs to assess meibomian gland structure during routine workups in any practice setting.
"Amid growing recognition of MGD as a core root cause of fluctuating vision and discomfort, we saw the need for a technology to make assessment of meibomian glands routine," said Joseph Boorady, OD, President and CEO of TearScience. "We are proud to transform care and lead innovation for MGD. LipiScan allows ECPs to evaluate meibomian gland structure in all patients. Because it is largely caused by modern lifestyles, many patients are at risk for MGD including surgical, contact lens and dry eye patients."
In the past year, TearScience embraced the feedback of ECPs by significantly adjusting prices of LipiView II and LipiFlow equipment and treatment Activators (Disposables). The introduction of LipiScan will allow busy practices to efficiently integrate assessment of meibomian glands and do so at an affordable price.
MGD is a prevalent chronic, obstructive and progressive disease that impacts the tear film, visual performance and ocular comfort. LipiFlow treatment for MGD is supported by significant science. A review of 31 sponsored and unsponsored peer-reviewed reports demonstrated that a single LipiFlow treatment typically improves mean meibomian gland secretions while reducing mean patient-reported symptom scores over sustained periods.1
According to Preeya Gupta, MD of Duke University, "TearScience provides professionals with innovations for evaluating meibomian glands and for truly effective treatment of MGD. TearScience is continuing to grow awareness of how MGD can affect overall ocular health."
TearScience, a medical device company, has pioneered technologies and leads innovation to vastly improve evaluation of meibomian glands and treatment of meibomian gland dysfunction (MGD). A progressive, obstructive disease and root cause of dry eye, MGD is distinguished by loss of function and structure of tear oil (meibomian) glands. MGD affects approximately 86% of the millions of dry eye sufferers worldwide and is highly prevalent in the general ophthalmic population. LipiView II and new LipiScan with Dynamic Meibomian Imaging™ (DMI) distinctively images meibomian gland structure. The Korb Meibomian Gland Evaluator™ assists physicians to reproducibly assess gland function. LipiFlow uses Vectored Thermal Pulse™ (VTP) technology to precisely direct treatment from the inner-lid and has received clearance by the US Food and Drug Administration for use in patients with MGD. Sponsored and unsponsored multicenter, randomized, controlled clinical studies of LipiFlow demonstrate its safety and sustained effectiveness. For additional information on how TearScience improves evaluation of meibomian glands, meibomian gland function, and symptoms for patients with MGD worldwide, visit www.TearScience.com.
1. Blackie, C. A., Carlson, A. N., & Korb, D. R. (2015). Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation. Current Opinion in Ophthalmology, 26(4), 306-313. Retrieved from http://tearscience.com/en/wp-content/uploads/455117X_21184-0187.pdf
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.